Short History of the issue at hand with this DEA Statute
Since October 24, 2018, when Congress passed Public Law 115-271, “SUPPORT Act”, DEA-registered pharmacies were extremely limited in their ability to deliver controlled substances directly to prescribing or administering practitioners. When Congress created 21 U.S.C. 829a in the statute, it only authorized such delivery for medications for opioid use disorder (MOUD), primarily Schedule III–V injectable or implantable products used for maintenance or detoxification treatment.
While this was a meaningful step in expanding access to MOUD, Congress did not account for non-MOUD controlled substances, such as medications used in implantable pain pumps, in-office procedures, or other direct administration therapeutic controlled substances. As a result, many providers faced logistical barriers, and pharmacies were unable to support legitimate medical use cases outside MOUD.
That changed on December 1, 2025, when Congress enacted Public Law 119-44, the SUPPORT for Patients and Communities Reauthorization Act of 2025. This new law amended 21 U.S.C. 829a to significantly broaden the scenarios in which a pharmacy may deliver a controlled substance directly to a practitioner.
What the Law Originally Allowed (2018 – 2025)
Under Public Law 115‑271, delivery from a pharmacy to a practitioner was limited to situations where:
- The controlled substance was a Schedule III–V MOUD controlled substance.
- It was to be administered only via injection or implantation for maintenance or detoxification; and
- It could not be used to supply a practitioner with general stock.
This left a gap for non-MOUD controlled substances that also require direct administration to a patient, such as those used in, interventional procedures, or other specialized medical treatments.
The 2025 Amendment: A Major Expansion
Public Law 119-44 (Dec. 1, 2025) updated 21 U.S.C. 829a to broaden pharmacy-to-practitioner delivery far beyond MOUD. The revised language now allows delivery of any Schedule III–V controlled substance that is approved or licensed to be administered by or under the supervision of a practitioner, not just those for detox or maintenance.
This expansion reflects Congress’s recognition that modern clinical practice includes numerous legitimate uses of Schedule III–V medications that require direct practitioner administration—many unrelated to substance use disorder treatment.
Key elements of the updated statute include:
- Broader applicability: Delivery now includes all Schedule III–V drugs approved for practitioner-administered use.
- Continued safeguards:
- No delivery may be used to supply practitioner stock.
- The substance must be administered to the named patient within 45 days of practitioner receipt.
- Both the prescribing and administering practitioner must maintain complete, accurate controlled substance records.
- State law must still authorize the activity; compliance remains a dual federal and state requirement.
Statute Comparison
This section outlines the key differences between the statutory language governing pharmacy-to-practitioner delivery of controlled substances before and after December 2025. While the pre-December 2025 provision permitted delivery only for certain narcotic drugs administered via injection or implantation for maintenance or detoxification treatment, the post-December 2025 language expands this authority. The updated statute broadens the scope to include additional Schedule III–V drugs administered under specific conditions, including those subject to Risk Evaluation and Mitigation Strategies (REMS) requiring post administration monitoring.
21 U.S.C. 829a, Pre-December 2025
“Notwithstanding section 802(10) of this title, a pharmacy may deliver a controlled substance to a practitioner in accordance with a prescription that meets the requirements of this subchapter and the regulations issued by the Attorney General under this subchapter, for the purpose of administering the controlled substance by the practitioner if
(1) the controlled substance is delivered by the pharmacy to the prescribing practitioner or the practitioner administering the controlled substance, as applicable, at the location listed on the practitioner’s certificate of registration issued under this subchapter;
(2) the controlled substance is a narcotic drug in schedule III, IV, or V to be administered for the purpose of maintenance or detoxification treatment and is to be administered by injection or implantation” …
21 U.S.C. 829a, Post December 2025
“Notwithstanding section 802(10) of this title, a pharmacy may deliver a controlled substance to a practitioner in accordance with a prescription that meets the requirements of this subchapter and the regulations issued by the Attorney General under this subchapter, for the purpose of administering the controlled substance by the practitioner if:
(1) the controlled substance is delivered by the pharmacy to the prescribing practitioner or the practitioner administering the controlled substance, as applicable, at the location listed on the practitioner’s certificate of registration issued under this subchapter;
(2) the controlled substance is a drug in schedule III, IV, or V to be administered—
(A) by injection or implantation for the purpose of maintenance or detoxification treatment; or
(B) subject to a risk evaluation and mitigation strategy pursuant to section 355–1 of this title that includes elements to assure safe use of the drug described in subsection (f)(3)(E) of such section, including a requirement for post-administration monitoring by a health care provider” …
Why This Matters for Pharmacies, Clinics, and Patients
- Expanded Access to In-Office Treatments
Pain management specialists, interventional clinicians, and certain surgical practices can now receive controlled substances directly from pharmacies for patient-specific administration, improving care efficiency.
- Reduced Logistical Barriers
Prior to the amendment, many providers struggled with supply-chain constraints when trying to obtain patient-specific controlled substances not tied to MOUD. This change supports smoother coordination between prescribers, pharmacists, and practitioners.
- Strong Regulatory Controls Remain
The amendment expands access, but does not relax compliance obligations. Practitioners must strictly adhere to DEA recordkeeping, patient-specific handling, and the 45-day administration window.
Practical Implications for Your Organization
This update substantially changes how pharmacies and practitioner offices may coordinate patient-specific controlled substances. Organizations should:
- Review and update SOPs governing procurement, delivery, and administration of Schedule III–V substances.
- Ensure recordkeeping systems capture all data required under 21 U.S.C. 829a.
- Confirm state law alignment, as federal authorization does not override state limitations.
- Train staff in both pharmacy and practitioner settings on the new expanded eligibility for delivery.
DEA Has Not Updated Their Regulations, What Do You Do?
Congress amended 21 U.S.C. 829a through Public Law 11944 on December 1, 2025, significantly expanding the authority for pharmacies to deliver Schedule III–V controlled substances directly to practitioners for administration. This statutory update overrides the original MOUD-only delivery framework established under Public Law 115271. Because federal statutes enacted by Congress carry higher legal authority than agency regulations, these updated statutory provisions control, even though DEA has not yet revised 21 CFR 1306.07(f) to reflect the expanded delivery allowances and continues to display the outdated requirements. Thus, when a conflict exists between the statute and the Code of Federal Regulations, registrants must follow the statute, as regulations cannot lawfully contradict or restrict the scope of congressional enactments.
As a result, DEA registrants should now operate under the broadened authority of the amended 21 U.S.C. 829a, even if the language in 21 CFR 1306.07(f) still includes older limitations—such as requiring a qualifying practitioner, limiting use to detox/maintenance treatment, or imposing a 14-day administration window—which no longer align with federal law. Because these regulatory provisions conflict with the updated statute, they are not enforceable to the extent of that conflict. Registrants should adjust policies, procedures, and recordkeeping to conform to current statutory requirements.
For further information or guidance on how to apply these changes, consult an attorney who specializes in DEA regulations. Brinks DEA Consulting recommends Deko Law.
Conclusion
The December 2025 amendment in Public Law 11944 represents a meaningful modernization of the Controlled Substances Act. By expanding 21 U.S.C. 829a beyond MOUD-specific delivery to include any approved Schedule III–V drug administered under practitioner supervision, Congress has aligned federal law with real-world medical practice, while maintaining the rigorous controls necessary to prevent diversion.
Brinks DEA Consulting can help pharmacies, clinics, and health systems update compliance frameworks, develop policies, and train staff to align with the new requirements.
If you’d like assistance in interpreting how this statutory change applies to your operation, we’re here to help.